The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer-Reference-Cited by-同舟云学术

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

Published:2011-06-10 Issue:2 Volume:3 Page:2667-2678
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Chang Shih-Chieh,Chang Cheng-Yu,Shih Jin-Yuan

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

http://www.mdpi.com/2072-6694/3/2/2667/pdf

Reference56 articles.

1. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit. Rev. Oncol. Hematol.,1995

2. EGFR antagonists in cancer treatment;Ciardiello;N. Engl. J. Med.,2008

3. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies;Ji;Cancer Cell,2006

4. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy;Paez;Science,2004

5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat. Rev. Cancer,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Adding Biological Factors to the Decision-Making Process for Spinal Metastasis of Non-Small Cell Lung Cancer;Journal of Clinical Medicine;2021-03-08

2. Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups;Spinal Cord;2019-09-09

3. Efficacy of gefitinib and radiotherapy combination in Indonesian patients with lung adenocarcinoma;Romanian Journal of Internal Medicine;2018-08-29

4. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR;Journal of Medicinal Chemistry;2017-03-29

5. Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene;Oncology Reports;2014-05-19